Is a 100% rally on the horizon? Evotec, D-Wave, and AI pearl NetraMark

NetraMark Holdings: AI for a market worth billions

NetraMark Holdings Inc. combines the opportunities of the megatrends artificial intelligence (AI) and biotech. The stock is still an AI insider tip. With the positive news flow of the past few weeks, the stock has jumped, but it still appears to be anything but expensive. Management also made a positive impression at the 14th IIF investor conference, demonstrating why the Company is a leading provider of generative AI software for analyzing clinical studies.

https://youtu.be/LQC5EHqRa4w?si=b-VgxdaN2jY5uJSs

Most recently, NetraMark presented two significant studies on major depressive disorder (MDD) and schizophrenia at the International Society for CNS Clinical Trials and Methodology (ISCTM) conference. Both confirmed that the NetraAI platform leverages the power of advanced machine learning in clinical trials. For research-based pharmaceutical and biotech companies, this means that they can conduct trials faster and more cost-effectively, thus bringing their drugs to market faster.

According to NetraMark, traditional machine learning (ML), including deep learning, often fails when modeling clinical trial data. NetraAI is designed to solve these problems. The AI platform is designed to identify optimal patient cohorts for future studies and to improve established ML methods. In the MDD study, for example, NetraAI-driven analysis of patient subpopulations achieved a 28% increase in model accuracy compared to conventional ML approaches. Sensitivity was improved by 31%, and specificity increased by 51%.

NetraAI also delivered convincing results in the schizophrenia study. Using data from the CATIE schizophrenia study, NetraAI identified clinically meaningful subpopulations that respond preferentially to olanzapine or perphenazine. As a result, patients with moderate to severe symptoms and mild behavioral disorders responded better to the drug olanzapine. Patients with moderate negative symptoms, mild to moderate hallucinations and paranoia showed an improved response to perphenazine.

Overall, NetraMark is confident that its AI-driven methods have the potential to improve clinical research and accelerate drug development significantly. In doing so, the AI specialist is tapping into a billion-dollar market.

Evotec: Is there a risk of further write-downs?

While NetraMark should win further customers in the current year, and the share price should benefit noticeably from this, Evotec is busy with itself. The clean-up and realignment of the new CEO will take some time. Investors still seem to expect some bad news. As a result, positive news is currently falling on deaf ears and the share price is threatening to fall back below EUR 6.

Evotec recently reported a breakthrough in its long-standing partnership with Bristol Myers Squibb. Based on the latest scientific success in their joint research into neurodegenerative diseases, Evotec will receive a milestone payment of USD 20 million. The funds will be used to further develop a promising preclinical program for the treatment of neurodegeneration.

The day before the announcement, Deutsche Bank reiterated its sell recommendation. Given the 2024 annual figures, which will be published soon, analysts expect an 11% increase in revenue. In terms of EBITDA, the experts expect an increase of 69%. However, there is currently some uncertainty regarding depreciation, amortization, and future strategy. The analysts believe that Evotec's shares are currently only worth EUR 4. From their point of view, there is still significant downside potential.

D-Wave: 100% possible?

In the tech sell-off of recent weeks, D-Wave's stock has also taken a beating. Since its all-time high at the beginning of January at just over USD 10, the security has now lost more than 50% of its value.

Analysts continue to hold the stock. According to marketscreener.com, six out of six analysts recommend buying the stock. In early March, B. Riley analysts confirmed their "Buy" recommendation with a price target of USD 11. This is currently the highest price target for quantum shares. However, earnings estimates for the fourth quarter of 2024 were slightly reduced. The analysts expect D-Wave to report a loss of USD 0.11. Previously, the forecast was a loss of USD 0.10.

According to marketscreener.com, the average price target is currently USD 7.67. In order to achieve this, D-Wave's share price would have to rise by 60%.

If analysts from B. Riley are correct, D-Wave's stock could be poised for a 100% rally. However, for that to happen, the sentiment towards AI and quantum stocks will likely have to improve first. NetraMark's stock is holding up surprisingly well in the recent tech sell-off. This shows that significantly higher prices are possible if conditions normalize - especially if the positive operational news flow continues. In contrast, buying Evotec stock isn't particularly compelling right now, although acquisition speculation could reignite at any time.